Janux Therapeutics (JANX) EPS (Weighted Average and Diluted) (2021 - 2026)
Janux Therapeutics (JANX) reported EPS (Weighted Average and Diluted) of -$0.39 for Q1 2026, down 2.63% year-over-year from -$0.4 in Q1 2025, and up 23.53% quarter-over-quarter from -$0.51 in Q4 2025.
Janux Therapeutics (JANX) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.39 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.39, down 2.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.84 (down 36.3% YoY), and the FY2025 annual result was -$1.83, down 42.97% from the prior year.
- EPS (Weighted Average and Diluted) grew to -$0.39 in Q1 2026 per JANX's latest filing, from -$0.51 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.11 in Q2 2024 and troughed at -$0.55 in Q2 2025.
- A 5-year average of -$0.37 and a median of -$0.39 in 2025 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) jumped 73.81% in 2024, then slumped 400.0% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.39 in 2022, then jumped by 38.46% to -$0.24 in 2023, then plunged by 45.83% to -$0.35 in 2024, then sank by 45.71% to -$0.51 in 2025, then climbed by 23.53% to -$0.39 in 2026.
- Business Quant data shows JANX's EPS (Weighted Average and Diluted) at -$0.39 in Q1 2026, -$0.51 in Q4 2025, and -$0.39 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Janux Therapeutics | 892.99 Mn | 892.99 Mn | - | -0.39 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.39 |
| Dec 31, 2025 | -0.51 |
| Sep 30, 2025 | -0.39 |
| Jun 30, 2025 | -0.55 |
| Mar 31, 2025 | -0.38 |
| Dec 31, 2024 | -0.35 |
| Sep 30, 2024 | -0.51 |
| Jun 30, 2024 | -0.11 |
| Mar 31, 2024 | -0.30 |
| Dec 31, 2023 | -0.24 |
| Sep 30, 2023 | -0.25 |
| Jun 30, 2023 | -0.42 |
| Mar 31, 2023 | -0.42 |
| Dec 31, 2022 | -0.39 |
| Sep 30, 2022 | -0.40 |
| Jun 30, 2022 | -0.41 |
| Mar 31, 2022 | -0.32 |
| Dec 31, 2021 | -0.29 |
| Sep 30, 2021 | -0.26 |
| Jun 30, 2021 | -0.62 |